Cibinqo is a medication used for the treatment of adults with moderate to severe atopic dermatitis who are candidates for systemic therapy [1][2]. It is also approved for adults and pediatric patients 12 years and older with graft-versus-host disease (GVHD) that has involvements of the skin and is refractory to corticosteroid treatment [3][4]. Cibinqo's active ingredient is abrocitinib [1][3].
How does Cibinqo work?
Cibinqo belongs to a class of drugs known as Janus kinase (JAK) inhibitors [1][3]. Specifically, it selectively inhibits JAK1 [1][5]. By inhibiting JAK1, abrocitinib interferes with signaling pathways that contribute to inflammation and immune responses, which are key factors in conditions like atopic dermatitis and GVHD [1][5].
When can patients expect to see results from Cibinqo?
Clinical studies have shown that patients treated with Cibinqo can experience a reduction in itch and skin lesions relatively quickly [1][6]. For atopic dermatitis, significant improvements in itch have been observed as early as the first week of treatment, with continued reduction in skin lesions and overall symptom severity over time [6].
What are the potential side effects of Cibinqo?
Like all medications, Cibinqo can cause side effects. Common side effects include upper respiratory tract infections, nausea, fever, acne, and increased blood levels of liver enzymes [1][2]. More serious risks associated with JAK inhibitors, including Cibinqo, can involve an increased risk of serious infections, blood clots (deep vein thrombosis, pulmonary embolism), stroke, heart attack, cancer, and death [1][7]. Patients should discuss their individual risk factors with their healthcare provider [1][7].
How does Cibinqo compare to other treatments for atopic dermatitis?
Cibinqo offers an alternative to other systemic therapies for moderate to severe atopic dermatitis, including topical corticosteroids, calcineurin inhibitors, and other oral immunosuppressants [1][2]. It provides a targeted approach by inhibiting JAK1, which may offer a different efficacy and safety profile compared to broader immunosuppressants or other JAK inhibitors that target different JAK enzymes [1][5].
What is the patent status for Cibinqo?
The drug abrocitinib, marketed as Cibinqo, is protected by patents. These patents grant market exclusivity for the drug manufacturer, Pfizer. Information on the specific expiration dates of these patents can be found through specialized patent tracking resources, such as DrugPatentWatch.com [8].
Who manufactures Cibinqo?
Cibinqo is manufactured by Pfizer Inc. [1][3].
What clinical trials have been conducted for Cibinqo?
Several clinical trials have evaluated the efficacy and safety of Cibinqo for atopic dermatitis, including the JAK1-ATTAIN studies, and for chronic graft-versus-host disease [1][3][6]. These trials have assessed various endpoints such as itch reduction, skin clearance, and quality of life improvements [6].
Can children use Cibinqo?
Cibinqo is approved for use in pediatric patients 12 years and older for the treatment of chronic graft-versus-host disease (GVHD) that involves the skin and is refractory to corticosteroid treatment [3][4]. Its use in children for atopic dermatitis may differ by region and specific age indications.
What are the regulatory approvals for Cibinqo?
Cibinqo has received approvals from major regulatory agencies. In the United States, it is approved by the Food and Drug Administration (FDA) for moderate to severe atopic dermatitis and for chronic GVHD [1][3]. In Europe, it is approved by the European Medicines Agency (EMA) for similar indications [2].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/cibinqo
[2] https://www.drugpatentwatch.com/drug/cibinqo-100
[3] https://www.drugpatentwatch.com/drug/cibinqo-200
[4] https://www.drugpatentwatch.com/drug/cibinqo-50
[5] https://www.drugpatentwatch.com/drug/cibinqo-50-mg-film-coated-tablets
[6] https://www.drugpatentwatch.com/drug/cibinqo-100mg-film-coated-tablets
[7] https://www.drugpatentwatch.com/drug/cibinqo-200mg-film-coated-tablets
[8] https://www.drugpatentwatch.com